1 |
Vellingiri B, Chandrasekhar M, Sri Sabari S, Gopalakrishnan AV, Narayanasamy A, Venkatesan D, Iyer M, Kesari K, Dey A. Neurotoxicity of pesticides - A link to neurodegeneration. Ecotoxicol Environ Saf 2022;243:113972. [PMID: 36029574 DOI: 10.1016/j.ecoenv.2022.113972] [Reference Citation Analysis]
|
2 |
Palese F, Pontis S, Realini N, Torrens A, Ahmed F, Assogna F, Pellicano C, Bossù P, Spalletta G, Green K, Piomelli D. Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonism. Pharmacol Res 2022;182:106338. [PMID: 35781057 DOI: 10.1016/j.phrs.2022.106338] [Reference Citation Analysis]
|
3 |
Sergeeva OA, Mazur K, Reiner-Link D, Lutsenko K, Haas HL, Alfonso-Prieto M, Stark H. OLHA (Nα-oleoylhistamine) modulates activity of mouse brain histaminergic neurons. Neuropharmacology 2022;215:109167. [PMID: 35750238 DOI: 10.1016/j.neuropharm.2022.109167] [Reference Citation Analysis]
|
4 |
Avagliano C, Coretti L, Lama A, Pirozzi C, De Caro C, De Biase D, Turco L, Mollica MP, Paciello O, Calignano A, Meli R, Lembo F, Mattace Raso G. Dual-Hit Model of Parkinson's Disease: Impact of Dysbiosis on 6-Hydroxydopamine-Insulted Mice-Neuroprotective and Anti-Inflammatory Effects of Butyrate. Int J Mol Sci 2022;23:6367. [PMID: 35742813 DOI: 10.3390/ijms23126367] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
5 |
Landolfo E, Cutuli D, Petrosini L, Caltagirone C. Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans. Biomolecules 2022;12:667. [DOI: 10.3390/biom12050667] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
6 |
Iranshahy M, Javadi B, Sahebkar A. Protective effects of functional foods against Parkinson's disease: A narrative review on pharmacology, phytochemistry, and molecular mechanisms. Phytother Res 2022. [PMID: 35244296 DOI: 10.1002/ptr.7425] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
|
7 |
Angelopoulou E, Paudel YN, Bougea A, Piperi C. Impact of the apelin/APJ axis in the pathogenesis of Parkinson's disease with therapeutic potential. J Neurosci Res 2021;99:2117-33. [PMID: 34115895 DOI: 10.1002/jnr.24895] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
8 |
Dutta R. Endocannabinoidome and its role in neurological disorders-A comprehensive update of existing literature. J Neurosci Neurol Disord 2021;5:034-047. [DOI: 10.29328/journal.jnnd.1001049] [Reference Citation Analysis]
|
9 |
Dmitry P. Perspectives of pharmacological correction and evaluation of mitochondrial dysfunction in neurodegenerative and ischemic brain lesions. Bioactive Natural Products 2021. [DOI: 10.1016/b978-0-12-819487-4.00018-5] [Reference Citation Analysis]
|
10 |
Petrosino S, Schiano Moriello A. Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries-A Systematic Review. Int J Mol Sci 2020;21:E9526. [PMID: 33333772 DOI: 10.3390/ijms21249526] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
11 |
D. Udovin L, Aguilar A, Kobiec T, I. Herrera M, Perez Lloret S, Toro Urrego N, A. Kölliker Frers R. Neuroprotective Properties of Cannabinoids in Cellular and Animal Models: Hypotheses and Facts. Neuroprotection - New Approaches and Prospects 2020. [DOI: 10.5772/intechopen.90761] [Reference Citation Analysis]
|
12 |
Beggiato S, Cassano T, Ferraro L, Tomasini MC. Astrocytic palmitoylethanolamide pre-exposure exerts neuroprotective effects in astrocyte-neuron co-cultures from a triple transgenic mouse model of Alzheimer's disease. Life Sci 2020;257:118037. [PMID: 32622942 DOI: 10.1016/j.lfs.2020.118037] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
13 |
Baptista LC, Sun Y, Carter CS, Buford TW. Crosstalk Between the Gut Microbiome and Bioactive Lipids: Therapeutic Targets in Cognitive Frailty. Front Nutr 2020;7:17. [PMID: 32219095 DOI: 10.3389/fnut.2020.00017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
|
14 |
Lama A, Pirozzi C, Avagliano C, Annunziata C, Mollica MP, Calignano A, Meli R, Mattace Raso G. Nutraceuticals: An integrative approach to starve Parkinson's disease. Brain Behav Immun Health 2020;2:100037. [PMID: 34589828 DOI: 10.1016/j.bbih.2020.100037] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
15 |
Udovin LD, Kobiec T, Herrera MI, Toro-Urrego N, Kusnier CF, Kölliker-Frers RA, Ramos-Hryb AB, Luaces JP, Otero-Losada M, Capani F. Partial Reversal of Striatal Damage by Palmitoylethanolamide Administration Following Perinatal Asphyxia. Front Neurosci 2019;13:1345. [PMID: 31969800 DOI: 10.3389/fnins.2019.01345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
16 |
Kao YC, Wei WY, Tsai KJ, Wang LC. High Fat Diet Suppresses Peroxisome Proliferator-Activated Receptors and Reduces Dopaminergic Neurons in the Substantia Nigra. Int J Mol Sci 2019;21:E207. [PMID: 31892244 DOI: 10.3390/ijms21010207] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
|
17 |
Peng T, Liu X, Wang J, Liu Y, Fu Z, Ma X, Li J, Sun G, Ji Y, Lu J, Wan W, Lu H. Fluoxetine-mediated inhibition of endoplasmic reticulum stress is involved in the neuroprotective effects of Parkinson's disease. Aging (Albany NY) 2018;10:4188-96. [PMID: 30585175 DOI: 10.18632/aging.101716] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
18 |
Beggiato S, Tomasini MC, Ferraro L. Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer's Disease. Front Pharmacol 2019;10:821. [PMID: 31396087 DOI: 10.3389/fphar.2019.00821] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
|
19 |
Zeng XS, Geng WS, Jia JJ. Neurotoxin-Induced Animal Models of Parkinson Disease: Pathogenic Mechanism and Assessment. ASN Neuro 2018;10:1759091418777438. [PMID: 29809058 DOI: 10.1177/1759091418777438] [Cited by in Crossref: 98] [Cited by in F6Publishing: 108] [Article Influence: 24.5] [Reference Citation Analysis]
|
20 |
Lange KW, Nakamura Y, Chen N, Guo J, Kanaya S, Lange KM, Li S. Diet and medical foods in Parkinson’s disease. Food Science and Human Wellness 2019;8:83-95. [DOI: 10.1016/j.fshw.2019.03.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
21 |
Davis MP, Behm B, Mehta Z, Fernandez C. The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review. Am J Hosp Palliat Care 2019;36:1134-54. [PMID: 31113223 DOI: 10.1177/1049909119850807] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
|
22 |
Zhu J, Dou S, Jiang Y, Chen J, Wang C, Cheng B. Apelin-13 protects dopaminergic neurons in MPTP-induced Parkinson's disease model mice through inhibiting endoplasmic reticulum stress and promoting autophagy. Brain Res 2019;1715:203-12. [PMID: 30914252 DOI: 10.1016/j.brainres.2019.03.027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
|
23 |
Ferguson LB, Zhang L, Wang S, Bridges C, Harris RA, Ponomarev I. Peroxisome Proliferator Activated Receptor Agonists Modulate Transposable Element Expression in Brain and Liver. Front Mol Neurosci 2018;11:331. [PMID: 30283300 DOI: 10.3389/fnmol.2018.00331] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
24 |
Gallelli CA, Calcagnini S, Romano A, Koczwara JB, de Ceglia M, Dante D, Villani R, Giudetti AM, Cassano T, Gaetani S. Modulation of the Oxidative Stress and Lipid Peroxidation by Endocannabinoids and Their Lipid Analogues. Antioxidants (Basel) 2018;7:E93. [PMID: 30021985 DOI: 10.3390/antiox7070093] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 9.2] [Reference Citation Analysis]
|
25 |
Kumari N, Agrawal S, Kumari R, Sharma D, Luthra PM. Neuroprotective effect of IDPU (1-(7-imino-3-propyl-2,3-dihydrothiazolo [4,5-d]pyrimidin-6(7H)-yl)urea) in 6-OHDA induced rodent model of hemiparkinson’s disease. Neuroscience Letters 2018;675:74-82. [DOI: 10.1016/j.neulet.2018.03.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
26 |
Cordaro M, Siracusa R, Crupi R, Impellizzeri D, Peritore AF, D'Amico R, Gugliandolo E, Di Paola R, Cuzzocrea S. 2-Pentadecyl-2-Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease. Mol Neurobiol 2018;55:9251-66. [PMID: 29656363 DOI: 10.1007/s12035-018-1064-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
|
27 |
Puglia C, Blasi P, Ostacolo C, Sommella E, Bucolo C, Platania CBM, Romano GL, Geraci F, Drago F, Santonocito D, Albertini B, Campiglia P, Puglisi G, Pignatello R. Innovative Nanoparticles Enhance N-Palmitoylethanolamide Intraocular Delivery. Front Pharmacol 2018;9:285. [PMID: 29643808 DOI: 10.3389/fphar.2018.00285] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
|
28 |
Goes AT, Jesse CR, Antunes MS, Lobo Ladd FV, Lobo Ladd AA, Luchese C, Paroul N, Boeira SP. Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson's disease: Involvement of neuroinflammation and neurotrophins. Chemico-Biological Interactions 2018;279:111-20. [DOI: 10.1016/j.cbi.2017.10.019] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 14.4] [Reference Citation Analysis]
|
29 |
Fu Q, Song R, Yang Z, Shan Q, Chen W. 6-Hydroxydopamine induces brain vascular endothelial inflammation: 6-OHDA Induces Brain Vascular Endothelial Inflammation. IUBMB Life 2017;69:887-95. [DOI: 10.1002/iub.1685] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
|
30 |
Herrera A, Muñoz P, Steinbusch HWM, Segura-Aguilar J. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease? ACS Chem Neurosci 2017;8:702-11. [PMID: 28233992 DOI: 10.1021/acschemneuro.7b00034] [Cited by in Crossref: 92] [Cited by in F6Publishing: 95] [Article Influence: 15.3] [Reference Citation Analysis]
|
31 |
Pistis M, Muntoni AL. Roles of N-Acylethanolamines in Brain Functions and Neuropsychiatric Diseases. Endocannabinoids and Lipid Mediators in Brain Functions 2017. [DOI: 10.1007/978-3-319-57371-7_11] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
32 |
Segura-Aguilar J. New preclinical model are required to discover neuroprotective compound in Parkinson's disease. Pharmacol Res 2017;119:490. [PMID: 27894922 DOI: 10.1016/j.phrs.2016.11.034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
33 |
Mattace Raso G, Avagliano C, Calignano A. Response to comment by Juan Segura-Aguilar: New preclinical model are required to discover neuroprotective compound in Parkinson's disease. Pharmacol Res 2017;119:491-2. [PMID: 27890814 DOI: 10.1016/j.phrs.2016.11.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|